LRRK2 and Parkinson disease: These genetic studies may pave the way for targeted therapies in selected subpopulations, such as an antisense oligonucleotide targeting the mutated superoxide dismutase (SOD1) enzyme in ALS [33], or glucocerebrosidase (GBA)-activators or leucine-rich repeat kinase 2 (LRRK2)-inhibitors targeting disease-causing mutations in GBA or LRRK2 respectively in Parkinson’s disease [34].